Kwai-Ming Jack Cheung

This inventor holds 9 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Cancer Research Technology Limited. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kwai-Ming Jack Cheung. Retrieved from https://idiyas.com/inventor/kwai-ming-jack-cheung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 77.8

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 7.5

ph-index = 3

Forward Citations = 35(Granted Patents)

Company Filing History:

9 out of 268

Cancer Research Technology Limited

patents

Years Active: 2016-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11897877 - Inhibitor compounds (2024-02-13),

2. 11046688 - Inhibitor compounds (2021-06-29),

3. 10479788 - Compounds that inhibit MPS1 kinase (2019-11-19),

4. 10188642 - Pharmacologically active compounds (2019-01-29),

5. 9895364 - Pharmacologically active compounds (2018-02-20),

6. 9890157 - Inhibitor compounds (2018-02-13),

7. 9834552 - Inhibitor compounds (2017-12-05),

8. 9409907 - Inhibitor compounds (2016-08-09),

9. 9334286 - Pharmacologically active compounds (2016-05-10),

Title: Kwai-Ming Jack Cheung: Innovator in Cancer Research

Introduction

Kwai-Ming Jack Cheung is a prominent inventor based in London, GB. He has made significant contributions to the field of cancer research, holding a total of 9 patents. His work focuses on developing therapeutic agents aimed at treating proliferative diseases, particularly cancer.

Latest Patents

Among his latest patents, Cheung has developed inhibitor compounds that are designed to inhibit the spindle checkpoint function of Monospindle 1 (Mps1) kinases. These compounds interact with the Mps1 kinase either directly or indirectly. The invention emphasizes the use of these compounds as therapeutic agents for the treatment and prevention of cancer. Additionally, the patents detail processes for the preparation of these compounds and pharmaceutical compositions that include them.

Career Highlights

Cheung is currently associated with Cancer Research Technology Limited, where he continues to advance his research and innovations. His work has been instrumental in the development of new therapeutic strategies in oncology.

Collaborations

He has collaborated with notable colleagues such as Swen Hoelder and Julian Blagg, contributing to a dynamic research environment focused on cancer treatment.

Conclusion

Kwai-Ming Jack Cheung's innovative work in developing therapeutic agents for cancer treatment showcases his dedication to advancing medical science. His contributions through patents and collaborations highlight the importance of research in combating proliferative diseases.

Profile summary based on public USPTO records.